Novo Nordisk Faces Market Reaction After CagriSema Trial

Novo Nordisk's experimental weight-loss drug CagriSema demonstrated a 15.7% reduction in body weight at 68 weeks for adults with obesity and type 2 diabetes, according to recent results from the REDEFINE 2 trial. This phase III trial involved 1,206 participants and confirmed the drug's superior efficacy compared to a 3.1% weight loss in the placebo group. Despite positive results, Novo Nordisk's shares fell by 8.1% as the weight loss did not surpass expectations set by other drugs like Eli Lilly's Zepbound. The study showed that CagriSema was generally safe and well-tolerated, with mild to moderate gastrointestinal side effects that lessened over time. Novo Nordisk plans to proceed with regulatory approval submissions by the first quarter of 2026. The company remains optimistic about CagriSema's potential to address obesity and type 2 diabetes on a global scale.